Recurring Revenue Is Becoming the Real Currency of ANZ Wellness and Beauty.

A single-location aesthetics clinic in Brisbane and a national medi-spa platform can post the same annual revenue and still be worth wildly different multiples to a buyer. The difference rarely comes down to brand, footprint or even margin. It comes down to whether the revenue repeats without the owner in the room.

That distinction is becoming the organising principle of wellness and beauty dealmaking globally, and it has direct implications for founders and operators across ANZ. Global beauty M&A accelerated sharply in the first quarter of 2026, with deal volume tracked by BeautyMatter up more than 40 percent year on year as strategics and private equity alike chased brands with strong community relevance and repeat engagement. At the same time, Beauty Independent's survey of investors and bankers points to a widening valuation gap: capital remains available, but real financial performance now matters more than category momentum or fundraising enthusiasm.

Why Recurring Revenue Commands a Premium

Nowhere is this clearer than in medical aesthetics, the fastest growing subsector of wellness and beauty. In the US, private equity firms are reportedly paying six to ten times EBITDA for owner-independent aesthetic practices with transferable provider contracts, according to Aesthetic Consulting, while discounting heavily where a large share of revenue depends on a single practitioner or the founder personally. Ankura's due diligence practice notes that medspas draw investor interest specifically because of their cash-pay structure and high customer retention, which together produce annuity-like revenue that is easier to underwrite than one-off transactional sales.

The logic is straightforward. A buyer is not really pricing this quarter's revenue. They are pricing the probability that revenue persists after the founder steps back, the marketing spend normalises and the business is folded into a larger platform. Membership models, subscription programs and structured treatment plans all convert a single sale into a predictable stream, and predictable streams are what allow a lower mid-market business to be underwritten at platform-level multiples rather than lifestyle-business multiples.

The ANZ Opportunity Is Still Underbuilt

This matters acutely in Australia and New Zealand, where the wellness and beauty landscape remains far more fragmented, and far less structured around recurring revenue, than comparable markets offshore. The Australian wellness economy was valued at more than 28 billion dollars in 2023 according to the Global Wellness Institute, spanning everything from aesthetic medicine to sleep clinics and preventive care, and continues to grow according to Business Franchise Australia. Yet outside of a handful of scaled platforms, most Australian aesthetic and wellness businesses remain single-site, founder-led operations that monetise transactionally, one visit and one invoice at a time.

That gap is the opportunity. In the US, industry estimates put PE consolidation of the medspa sector at roughly three to four percent of locations, according to Aesthetic Brokers, leaving the large majority of the market independently owned even after several years of active roll-up activity. Australia's consolidation curve sits even further behind. For lower mid-market operators willing to build the infrastructure now, membership tiers, retention programs, standardised treatment protocols, that gap between transactional revenue and recurring revenue is exactly where enterprise value gets created before a platform sale ever happens.

What This Means in Practice

For founders, the practical takeaway is not to chase a subscription model as a marketing gimmick. It is to genuinely restructure the client relationship around retention: pre-paid treatment packages, membership pricing for ongoing care, loyalty structures that reward repeat visits over one-off purchases. Buyers can tell the difference between recurring revenue that is contractually or behaviourally embedded and recurring revenue that exists only on a slide.

For co-investors and operators evaluating platforms in this space, the diligence question worth asking earlier than most is not "how big is the revenue" but "how much of it survives a change of ownership." A clinic generating eight million dollars a year built almost entirely on the founder's personal client book is a different asset, and a different multiple, than one generating the same revenue through a membership base with multiple credentialed providers.

We think the lower mid-market wellness and beauty businesses across ANZ that build genuine recurring revenue architecture now, rather than retrofitting it for a sale process later, will be the ones best positioned to participate in the consolidation wave already reshaping this category globally.

Let's Talk

If you're building a wellness or beauty business in the lower mid-market and thinking about what durable, buyer-ready revenue actually looks like, we'd welcome the conversation.

Sources

• Why Beauty Is The Hottest Bet In Consumer M&A, Forbes
• Beauty's 2026 M&A Forecast, Beauty Independent
• The Ultimate Guide to Aesthetic M&A in 2026, Aesthetic Consulting
• Unlocking Value in the Medspa Sector, Ankura
• How Private Equity Buys Med Spas, Aesthetic Brokers
• Wellness Trends in Australia, Business Franchise Australia

This article is provided for general informational purposes only and does not constitute financial, investment, legal or tax advice, nor an offer, solicitation or recommendation in respect of any security, fund or transaction. Views expressed are those of Astra Capital Proprietary Limited ACN 691553849 at the time of publication and may change without notice. Information sourced from third parties is believed to be reliable but has not been independently verified and no warranty is given as to its accuracy or completeness. Past performance and industry trends are not indicative of future results. Readers should seek independent professional advice before making any investment decision. © Astra Capital Proprietary Limited ACN 691553849. All rights reserved.